Treatment with complete surgical metastasectomy (CM) for patients with metastatic renal cell carcinoma (mRCC) may be associated with improved survival, compared to incomplete or no metastasectomy (no-CM), according to a study published in The Journal of Urology.1
Researchers conducted a meta-analysis of 8 published cohort studies at low or moderate potential for bias that were identified through the Ovid Embase, Medline, and Cochrane, as well as Scopus databases, to evaluate the use of CM in mRCC.
They included only comparative studies that reported adjusted hazard ratios for all-cause mortality of no-CM compared to CM, using generic inverse variance with random effects models to determine the pooled adjusted hazard ratios.
Continue Reading
Among 2267 patients, 958 of whom had undergone CM, and 1309 of whom went with no-CM, CM was associated with a reduced risk of all-cause mortality compared with no-CM.
RELATED: First-line Sunitinib and Pazopanib Are Similarly Effective on mRCC
Median overall survival ranged between 36.5 to 142 months for those undergoing CM, compared to 8.4 to 27 months for those who went with no-CM. CM remained independently associated with reduction in mortality across a priori subgroup and sensitivity analysis, regardless of adjustment for performance status.
Reference
- Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. In press.
